Blood Glucose Control

When managing type 2 diabetes, most people focus on blood sugar. However, what if one medication could also improve heart health at the same time? That is exactly what researchers are discovering about how GLP-1 drugs affect blood pressure. These medications, originally designed to control glucose, are now showing consistent …

Type 2 diabetes management has evolved rapidly over the past decade. As new therapies improve glucose control and cardiometabolic outcomes, many patients achieve better metabolic stability than before. However, this progress often comes with a challenge: medication overload. Deprescribing in diabetes care has emerged as a thoughtful clinical approach that …

Continuous ketone monitoring for diabetes is emerging as one of the most intriguing developments in metabolic care. For decades, clinicians relied on periodic blood or urine tests to detect rising ketones. However, those methods often identify problems only after metabolic imbalance has already progressed. In contrast, newer sensor systems promise …

GLP-1 receptor agonists and dual incretin therapies are transforming diabetes care. These medications often produce significant and rapid improvements in glycemic control, sometimes lowering A1C levels faster than traditional treatments. However, clinicians have begun asking an important question: could rapid A1C reduction with GLP-1 therapy increase retinopathy risk in some …

Managing the risk of hypoglycemia remains a central challenge in diabetes care, even as newer therapies lower the rate of severe events. Although GLP-1 receptor agonists and SGLT2 inhibitors have reshaped treatment strategies, insulin and sulfonylureas are still widely used, especially among older adults and patients with chronic kidney disease …

Continuous glucose monitoring has transformed diabetes care, but are we fully using the data it provides? In 2026, time in range is moving beyond a simple CGM metric and becoming a formal therapeutic target in diabetes care. While A1C remains important, time in range (TIR) offers a more dynamic and …

When managing type 2 diabetes, should clinicians still begin with one medication and wait for treatment failure before intensifying therapy? Increasingly, evidence suggests that early combination therapy in type 2 diabetes may provide better durability, faster glycemic control, and improved cardiovascular and kidney outcomes in high-risk patients. While metformin monotherapy …

As GLP-1 receptor agonists become a mainstay in type 2 diabetes and obesity care, more patients are pairing medication with structured training programs. However, how do GLP-1 medications actually influence metabolism during exercise? Questions about fueling, endurance, fatigue, and muscle adaptation are becoming more common in clinical practice. The relationship …

The arrival of a once-weekly basal insulin option marks one of the most meaningful advances in insulin therapy in decades. For years, daily basal injections have been the standard of care for people with type 1 and type 2 diabetes. However, many patients struggle with adherence, missed doses, and therapeutic …

Diabetes management often begins with nutrition advice. However, what happens when patients cannot afford fresh produce or live miles from a grocery store? For many people living with diabetes, food insecurity is a growing yet underrecognized barrier to glycemic control. While clinicians routinely discuss carbohydrate counting and meal planning, they …